HIGHTIDE-B Receives NMPA Acceptance for New Drug Application of HTD1801

Stock News

Mar 10

HIGHTIDE-B (02511) announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for HTD1801 for the treatment of Type 2 Diabetes (T2DM). This marks the company's first NDA submission and represents a significant milestone in its path toward product commercialization. HTD1801 has completed three multicenter, randomized, double-blind, controlled Phase III clinical studies for the T2DM indication, all of which met primary and multiple secondary endpoints. The drug demonstrated consistent improvement trends across key cardiorenal metabolic dimensions, including blood glucose, blood lipids, inflammation, and renal function, highlighting its clinical value of multi-effect and comprehensive benefits.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1181902635"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181902635\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181902635?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 17:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181902635","market":"us","top_or_hot":-1,"title":"HIGHTIDE-B Receives NMPA Acceptance for New Drug Application of HTD1801","media":"Stock News","content":"<p>HIGHTIDE-B (02511) announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for HTD1801 for the treatment of Type 2 Diabetes (T2DM). This marks the company's first NDA submission and represents a significant milestone in its path toward product commercialization. HTD1801 has completed three multicenter, randomized, double-blind, controlled Phase III clinical studies for the T2DM indication, all of which met primary and multiple secondary endpoints. The drug demonstrated consistent improvement trends across key cardiorenal metabolic dimensions, including blood glucose, blood lipids, inflammation, and renal function, highlighting its clinical value of multi-effect and comprehensive benefits.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HIGHTIDE-B Receives NMPA Acceptance for New Drug Application of HTD1801</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHIGHTIDE-B Receives NMPA Acceptance for New Drug Application of HTD1801\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-10 17:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HIGHTIDE-B (02511) announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for HTD1801 for the treatment of Type 2 Diabetes (T2DM). This marks the company's first NDA submission and represents a significant milestone in its path toward product commercialization. HTD1801 has completed three multicenter, randomized, double-blind, controlled Phase III clinical studies for the T2DM indication, all of which met primary and multiple secondary endpoints. The drug demonstrated consistent improvement trends across key cardiorenal metabolic dimensions, including blood glucose, blood lipids, inflammation, and renal function, highlighting its clinical value of multi-effect and comprehensive benefits.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02511","symbol_name":"君圣泰医药-B","start_time":0,"source_url":"","article_id":"1181902635","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181902635","pubTimestamp":1773134896,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HIGHTIDE-B (02511) announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for HTD1801 for the treatment of Type 2 Diabetes (T2DM). This...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02511":"君圣泰医药-B","BK1161":"生物科技"},"translate_title":"海泰德-B HTD1801新药申请获NMPA受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02511":1},"content_text":"HIGHTIDE-B (02511) announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for HTD1801 for the treatment of Type 2 Diabetes (T2DM). This marks the company's first NDA submission and represents a significant milestone in its path toward product commercialization. HTD1801 has completed three multicenter, randomized, double-blind, controlled Phase III clinical studies for the T2DM indication, all of which met primary and multiple secondary endpoints. The drug demonstrated consistent improvement trends across key cardiorenal metabolic dimensions, including blood glucose, blood lipids, inflammation, and renal function, highlighting its clinical value of multi-effect and comprehensive benefits.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}